Meta-Analysis Of Safety And Efficacy Following Mitral Regurgitation Repair Using The Mitra Clip System

Objectives: The authors investigated safety and efficacy of the MitraClipSystem(MC-S)using a systematic analysis.Background: The safety and efficacy of the MC-S continues to be debated,and randomized trials are still lacking.Method: Using a common medical and scientific database for systematic literature searches,the following results were analyzed: 30-day and 12-month adverse events,mortality,reoperation rates,mitral regurgitation> 2+,New York Heart Function,6 Minute walking distance and echocardiography.Results: A total of 1555 patients who were systematically treated with MitraClip were analyzed.The age-weighted average was 68.9±11;MR>2+ patients were 10%and 13.5% at 30 days and 1 year after surgery,which was 90% and 86.5% lower than before surgery;NYHA>II grade patients were better at 30 days and 1 year.The former was reduced by 74.5% and 82.7%;the 1-year echocardiographic results showed that the end-diastolic volume and inner diameter were significantly reduced compared with before,being 23.64 ml and 0.36 cm.The end-systolic diameter and volume were slightly improved,and the reduction was 10.23 ml and 0.28 cm.There was no significant change in the ejection fraction;the walking distance at 6 minutes in one year was 82 meters longer than before;the 30-day and 1-year mortality rates were 3.4% and 19.4%,and the reoperation rate was 3.2% and 11.4%.Conclusion: For patients with limited surgical options,MitraClip system therapy is safe and effective.This method can significantly reduce valve anti-flow,improve heart function,reverse ventricular remodeling,high success rate of surgery,and low mortality and adverse events.Prospective randomized controlled trials are still needed to help identify potential adverse events,equipment durability,and long-term follow-up.